AtriCure Inc (OQ:ATRC)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 7555 Innovation Way MASON OH 45040 |
| Tel: | N/A |
| Website: | https://www.atricure.com |
| IR: | See website |
| Key People | ||
| Michael H. Carrel President, Chief Executive Officer, Director | Angela L. Wirick Chief Financial Officer | Douglas J. Seith Chief Operating Officer |
| Deborah Yount Chief Human Resource Officer | Salvatore Privitera Chief Technical Officer | Justin J. Noznesky Chief Marketing and Strategy Officer |
| Vinayak Doraiswamy Chief Scientific Officer | Karl S. Dahlquist Chief Legal Officer | |
| Business Overview |
| AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, AtriCure Inc revenues increased 21% to $399.2M. Net loss decreased 34% to $30.4M. Revenues reflect Appendage Management segment increase of 19% to $134.5M, Open-Heart Ablation segment increase of 22% to $105.3M, United States segment increase of 20% to $333.5M, Europe segment increase of 26% to $38.5M. Lower net loss reflects Interest Income increase of 90% to $3.8M (income). |
| Employees: | 1,200 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,067M as of Dec 31, 2023 |
| Annual revenue (TTM): | $399.25M as of Dec 31, 2023 |
| EBITDA (TTM): | -$11.87M as of Dec 31, 2023 |
| Net annual income (TTM): | -$30.44M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$37.51M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 48,374,624 as of Mar 18, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.